Physician profile
Ramit Singla
NPI 1427586908
$1,496.51
in general payments reported to CMS, 2019-2025
15 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $74.24 · 2021: $251 · 2022: $545 · 2023: $360 · 2024: $75.25 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $438.56 | 2021-2022 | |
| Ucb, INC. | $196.71 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Medtronic, INC. | $134.59 | 2023 | Linq II |
| Csl Behring | $122.55 | 2022 | |
| Eisai INC. | $117.66 | 2023-2024 | |
| Kyowa Kirin, INC. | $106.27 | 2022 | |
| Genzyme Corporation | $94.89 | 2022 | |
| Neurelis, INC. | $91.85 | 2020-2021 | |
| Chiesi USA, INC. | $91.57 | 2023 | Cleviprex |
| Acadia Pharmaceuticals INC | $19.39 | 2025 | Nuplazid |
| Cycle Pharmaceuticals INC | $18.74 | 2025 | Bafiertam, Tascenso Odt |
| Abbvie INC. | $17.98 | 2025 | |
| Upsher-Smith Laboratories LLC | $16.25 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.95 | 2024 | Horizant |
| Neurocrine Biosciences, INC. | $14.55 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramit Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.